BPC 157 for Acute Hamstring Muscle Strain Repair

What Was Tested

In this phase 2 trial, researchers set out to test BPC-157.

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain.

Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program.

The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

It had two arms (groups): Arm 1: Experimental - BPC 157 (experimental) and Arm 2: Placebo Comparator - Placebo (experimental).

Participants receive investigational pentadecapeptide BPC 157 plus standardized rehabilitation.

Participants receive matching placebo plus standardized rehabilitation.

The registry classes the interventions as drug.

More on the Plan

Acute hamstring strains are common in running- and field-based sports and often lead to prolonged time away from sport and a risk of recurrence.

After screening and baseline assessments (including MRI confirmation of an acute grade II hamstring strain), eligible participants will be randomized 1:1 to receive subcutaneous BPC 157 or matching placebo once daily for 14 days.

All participants will follow the same evidence-based rehabilitation protocol supervised by study physiotherapists.

Clinical assessments will occur at Days 3, 7, 14, 28, and 56, with additional follow-up at 3 months after return-to-play for recurrence monitoring.

Who Took Part

The registry lists 120 planned participants were the target.

It was open to people of any sex aged from 18 years up to 45 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 to 45 years. Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening. MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion. Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport. Willingness to follow the standardized rehabilitation protocol and attend all study visits.

The full record lists 6 inclusion and 10 exclusion criteria; among the exclusions: grade iii hamstring tear, tendon avulsion, or injury requiring surgical management; concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment; prior hamstring strain on the index limb within the past 6 months.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Because people in this BPC-157 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The BPC-157 group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received BPC-157.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-02-02 with completion listed for 2027-02-14.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Time to return to unrestricted sport participation (days) (time frame: 8 Weeks). Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review (time frame: 14 Days).

It also tracked 3 secondary outcomes, for example Change in pain during activity on a 0-10 Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain), Hamstring strength limb symmetry index (LSI) by isokinetic dynamometry and Change in Lower Extremity Functional Scale (LEFS; 0-80, higher scores indicate better function).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of BPC-157 in 120 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the BPC-157 compound page, all human trials.